News UK aims to cut four years from drug development process NICE, regulator and NHS should work together, according to review.
UK & Europe NICE says Otezla's bargain price offsets lower efficacy Otezla cheap and convenient, but less effective than rivals, says NICE.
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News Vertex seeks deal after NICE rejects CF drug Orkambi Company in talks with NICE over patient access scheme.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
